Vesalius is revolutionizing the way common illnesses are understood and treated. Vesalius's DIAMOND technology platform allows the company to see through disease complexity to more fully understand the drivers of common illnesses, enabling a far more effective and efficient approach to drug development. Vesalius's platform begins and ends with patients. It elegantly combines human data, genetics and genomics information, artificial intelligence and machine learning, and proprietary experimental models to redefine how we think about and treat common illnesses. Vesalius was founded in 2019 in Flagship Labs, Flagship Pioneering's innovation foundry.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/02/22 | $75,000,000 |
Flagship Pioneering | undisclosed |
